Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.
American Funds Corporate Bond A BFCAX
- NAV / 1-Day Return 9.76 / −0.09 %
- Total Assets 2.0 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.710%
- Distribution Fee Level Low
- Share Class Type Front Load
- Category Corporate Bond
- Credit Quality / Interest Rate Sensitivity Medium/Moderate
- Min. Initial Investment 250
- Status Open
- TTM Yield 3.76%
- Effective Duration 7.07 years
USD | NAV as of Sep 26, 2024 | 1-Day Return as of Sep 26, 2024, 10:10 PM GMT+0
Morningstar’s Analysis BFCAX
Will BFCAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 12.7
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Capital Group Central Cash Fund | 4.78 | 88.2 Mil | Cash and Equivalents |
United States Treasury Bonds 4.625% | 2.25 | 41.6 Mil | Government |
United States Treasury Notes 4.375% | 1.68 | 30.9 Mil | Government |
United States Treasury Notes 4.25% | 1.64 | 30.3 Mil | Government |
AbbVie Inc. 5.05% | 1.44 | 26.6 Mil | Corporate |
Pfizer Investment Enterprises Pte Ltd. 4.75% | 1.30 | 24.0 Mil | Corporate |
Cash And Other Assets Less Liablities | 1.16 | 21.5 Mil | Cash and Equivalents |
United States Treasury Bonds 4.25% | 0.97 | 17.9 Mil | Government |
JPMorgan Chase & Co. 5.581% | 0.90 | 16.6 Mil | Corporate |
Bristol-Myers Squibb Company 5.2% | 0.87 | 16.0 Mil | Corporate |